Navigation Links
Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
Date:9/7/2011

LAUSANNE, Switzerland, and MALVERN, Pennsylvania, September 7, 2011 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascenta Therapeutics, Inc. (Ascenta), a privately-held, biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer, have entered into an exclusive worldwide license agreement concerning the development and commercialization of AT-406 (called Debio 1143 by Debiopharm) a small molecule IAP inhibitor currently in phase I development. By targeting inhibitors of apoptosis proteins, AT-406 (or Debio 1143) can induce cancer cell death and/or potentiate the efficacy of other treatments and is expected to be effective in the treatment of various cancers in combination with anti-cancer therapies.


"We are very excited about this collaboration with Ascenta Therapeutics. This company has an impressive scientific team and expertise in the field of apoptosis", said Dr Rolland-Yves Mauvernay, president and founder of Debiopharm S.A., who added "it should be possible to combine AT-406 (or Debio 1143) with other pro-apoptotic agents, which can potentially bring huge benefits to patients by enhancing the efficiency of the treatment."

"Ascenta is pleased to form this partnership with Debiopharm, a company that has demonstrated a commitment to and expertise in the development of medicines to help cancer patients", noted Dr. Mel Sorensen, President and CEO of Ascenta.

About AT-406

AT-406 is an orally available small molecule that neutralizes major inhibitors of apoptosis. Apoptosis, or "programmed cell death," is a precisely regulated, complex process ensuring that defective, damaged or superfluous cells are eliminated. Evasion of apoptosis is a hallmark of cancer, enabling cancer cells to live indefinitely and grow uncontrollably. Most current cancer therapies
'/>"/>

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Japanese Cancer Association and Debiopharm Honour Japanese Research
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
6. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
7. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015   GenoSpace , ... the interpretation and analysis of genomic and other ... has joined the company as Vice President ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners ... integrate, interpret, analyze and explore complex sets of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading ... clinical study of its canine osteoarthritis stem cell product, currently under development for ... KS) and will be marketed in the US by Aratana. This product, termed ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/30/2015)... NH (PRWEB) , ... July 30, 2015 , ... ... homogenizer for advanced fluid applications and designed for continuous operation up to 1500 ... and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... , NEWPORT, Ky., July 13 ... development and commercial capabilities focused on women,s healthcare and pain ... its executive management team. Joining the company are Natasha ... Officer; and Peter Wentworth, Senior Vice President, Human Resources. ...
... PHILADELPHIA and LONDON, July 13 Thomson Reuters today ... the last two decades in both the volume and impact of ... findings underscore Brazil,s standing among the emergent "BRIC" nations. BRIC ... the countries possessing the resources and economic potential to capture a ...
... HOLMDEL, N.J., July 13 Sparta Systems, ... management software, today announced that Cangene Corporation, a ... Sparta,s TrackWise ((R)) Enterprise Quality Management software to ... operations in Canada and the United States. After ...
Cached Biology Technology:Xanodyne Announces New Executive Team Members 2Brazil's Scientific Research On The Rise, Thomson Reuters Study Finds 2Sparta Systems' TrackWise(R) Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 2Sparta Systems' TrackWise(R) Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 3Sparta Systems' TrackWise(R) Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 4
(Date:7/8/2015)... 2015 The consumer products industry for ... have products such as wearables, smart wallets & other smart ... based devices continues to rapidly grow.  Biometrics & Wearable Device ... ), Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... Inc. (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: ...
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
(Date:7/2/2015)... Fingerprint Cards has received an order ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... by smartphone manufacturers in Asia . The ... revenue guidance of approximately 2,200 MSEK for 2015. ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... Award on 25 March 2009 at the Spring Scientific Meeting ... the State Department of Agriculture & Food, Backweston Campus, Ireland. ... who is actively involved in and has made a substantial ... meeting was attended by about 30 members of the Society ...
... record usually shows what adult animals looked like. But ... dramatically from those of the adults. A classic example ... Uppsala, Cambridge and Duke Universities, published in Science ... animals also underwent such changes of lifestyle as they ...
... in Spanish . , KRas is one ... that is mutated in 30% of human tumors and has ... For this reason, it is one of the main focuses ... to publish new information relating to its molecular biology. Researchers ...
Cached Biology News:The life histories of the earliest land animals 2New data on the breakdown of the KRas protein 2
... to reward the animal for foraging behavior.The Spatial ... built around a video camera, frame grabber, and ... fields at once and up to 6 moving ... records them, but also allows video replay of ...
... Feature Extraction Software reads and ... to prepare microarray data for ... * one 1-year license ... NFP/Academic accounts ,one CD-ROM containing ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
Biology Products: